Literature DB >> 23774439

Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety.

Ran He1, Michael Forman, Bryan T Mott, Rajkumar Venkatadri, Gary H Posner, Ravit Arav-Boger.   

Abstract

We report that the artemisinin-derived dimer diphenyl phosphate (DPP; dimer 838) is the most selective inhibitor of human cytomegalovirus (CMV) replication among a series of artemisinin-derived monomers and dimers. Dimer 838 was also unique in being an irreversible CMV inhibitor. The peroxide unit within artemisinins' chemical structures is critical to their activities, and its absence results in loss of anti-CMV activities. Surprisingly, the deoxy dimer of 838 retained modest anti-CMV activity, suggesting that the DPP moiety of dimer 838 contributes to its anti-CMV activities. DPP alone did not inhibit CMV replication, but triphenyl phosphate (TPP) had modest CMV inhibition, although its selectivity index was low. Artemisinin DPP derivatives dimer 838 and monomer diphenyl phosphate (compound 558) showed stronger CMV inhibition and a higher selectivity index than their analogs lacking the DPP unit. An add-on and removal assay revealed that removing DPP derivatives (compounds 558 and 838) but not the non-DPP backbones (artesunate and compound 606) at 24 h postinfection (hpi) already resulted in dominant CMV inhibition. CMV inhibition was fully irreversible with 838 and partially irreversible with 558, while non-DPP artemisinins were reversible inhibitors. While all artemisinin derivatives and TPP reduced the expression of the CMV immediate early 2 (IE2), UL44, and pp65 proteins at or after 48 hpi, only TPP inhibited the expression of both IE1 and IE2. Combination of a non-DPP dimer (compound 606) with TPP was synergistic in CMV inhibition, while ganciclovir and TPP were additive. Although TPP shared structural similarity with monomer DPP (compound 558) and dimer DPP (compound 838), its pattern of CMV inhibition was significantly different from the patterns of the artemisinins. These findings demonstrate that the DPP group contributes to the unique activities of compound 838.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774439      PMCID: PMC3754318          DOI: 10.1128/AAC.00893-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials.

Authors:  I R Ribeiro; P Olliaro
Journal:  Med Trop (Mars)       Date:  1998

2.  Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses.

Authors:  Thomas Efferth; Manfred Marschall; Xin Wang; Shu-Mei Huong; Ilona Hauber; Armin Olbrich; Martina Kronschnabl; Thomas Stamminger; Eng-Shang Huang
Journal:  J Mol Med (Berl)       Date:  2001-12-08       Impact factor: 4.599

3.  Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation.

Authors:  Y Tanaka; Y Kanda; M Kami; S Mori; T Hamaki; E Kusumi; S Miyakoshi; Y Nannya; S Chiba; Y Arai; K Mitani; H Hirai; Y Mutou
Journal:  Bone Marrow Transplant       Date:  2002-09       Impact factor: 5.483

4.  The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.

Authors:  Suzanne J F Kaptein; Thomas Efferth; Martina Leis; Sabine Rechter; Sabrina Auerochs; Martina Kalmer; Cathrien A Bruggeman; Cornelis Vink; Thomas Stamminger; Manfred Marschall
Journal:  Antiviral Res       Date:  2005-11-21       Impact factor: 5.970

5.  Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers.

Authors:  G H Posner; P Ploypradith; M H Parker; H O'Dowd; S H Woo; J Northrop; M Krasavin; P Dolan; T W Kensler; S Xie; T A Shapiro
Journal:  J Med Chem       Date:  1999-10-21       Impact factor: 7.446

6.  Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines.

Authors:  Adebusola A Alagbala; Andrew J McRiner; Kristina Borstnik; Tanzina Labonte; Wonsuk Chang; John G D'Angelo; Gary H Posner; Barbara A Foster
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

7.  Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication.

Authors:  Ran He; Kyoungsook Park; Hongyi Cai; Arun Kapoor; Michael Forman; Bryan Mott; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

Review 8.  Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside.

Authors:  Thomas Efferth
Journal:  Planta Med       Date:  2007-03-12       Impact factor: 3.352

9.  Artesunate combinations for treatment of malaria: meta-analysis.

Authors:  M Adjuik; A Babiker; P Garner; P Olliaro; W Taylor; N White
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

10.  Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.

Authors:  Michael Y Shapira; Igor B Resnick; Sunwen Chou; Avidan U Neumann; Nell S Lurain; Thomas Stamminger; Orit Caplan; Niveen Saleh; Thomas Efferth; Manfred Marschall; Dana G Wolf
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

View more
  13 in total

1.  Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.

Authors:  Sujayita Roy; Ran He; Arun Kapoor; Michael Forman; Jennifer R Mazzone; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

Authors:  Blake S Moses; Samantha McCullough; Jennifer M Fox; Bryan T Mott; Søren M Bentzen; MinJung Kim; Jeffrey W Tyner; Rena G Lapidus; Ashkan Emadi; Michelle A Rudek; Tami J Kingsbury; Curt I Civin
Journal:  Blood Adv       Date:  2021-02-09

3.  Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.

Authors:  Breanna Barger-Kamate; Michael Forman; Cheik Oumar Sangare; Aboubecrin Sedhigh A Haidara; Hamma Maiga; Dhananjay Vaidya; Abdoulaye Djimde; Ravit Arav-Boger
Journal:  J Clin Virol       Date:  2016-02-11       Impact factor: 3.168

4.  The absence of p53 during Human Cytomegalovirus infection leads to decreased UL53 expression, disrupting UL50 localization to the inner nuclear membrane, and thereby inhibiting capsid nuclear egress.

Authors:  Man I Kuan; John M O'Dowd; Elizabeth A Fortunato
Journal:  Virology       Date:  2016-08-04       Impact factor: 3.616

5.  Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition.

Authors:  Sujayita Roy; Arun Kapoor; Fei Zhu; Rupkatha Mukhopadhyay; Ayan Kumar Ghosh; Hyun Lee; Jennifer Mazzone; Gary H Posner; Ravit Arav-Boger
Journal:  J Biol Chem       Date:  2020-08-27       Impact factor: 5.157

6.  The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.

Authors:  E Oiknine-Djian; Y Weisblum; A Panet; H N Wong; R K Haynes; D G Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Guidance for the management of adult patients with coronavirus disease 2019.

Authors:  Jie-Ming Qu; Chen Wang; Bin Cao
Journal:  Chin Med J (Engl)       Date:  2020-07-05       Impact factor: 2.628

Review 8.  Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions.

Authors:  Vera A Vil'; Ivan A Yaremenko; Alexey I Ilovaisky; Alexander O Terent'ev
Journal:  Molecules       Date:  2017-11-02       Impact factor: 4.411

Review 9.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08

Review 10.  Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function.

Authors:  Catherine S Adamson; Michael M Nevels
Journal:  Viruses       Date:  2020-01-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.